| Bioactivity | Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy. |
| Target | IC50: 0.6 nM (PD-1) |
| Invitro | Pembrolizumab (MK-3475) increases the secretion of cytokines IFN-γ, TNF-α and the apoptotic cell death of A549 cells[2]. Pembrolizumab improves the αROR1-CAR T-mediated cytotoxicity, and reduces tumorigenesis in the co-cultured αROR1-CAR T and A549 cells by blocking PD-1::PD-L1 interaction in αROR1-CAR T cells[2]. Cell Cytotoxicity Assay[2] Cell Line: |
| In Vivo | Pembrolizumab inhibits tumor size in A549 xenograft mice pretreated by pressure[2]. Animal Model: |
| Name | Pembrolizumab |
| CAS | 1374853-91-4 |
| Molar Mass | 146266.23 |
| Appearance | Liquid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017 Aug 16. pii: S0140-6736(17)31601-X. [2]. Zhenglin Ou, et al. Pressure increases PD‑L1 expression in A549 lung adenocarcinoma cells and causes resistance to anti‑ROR1 CAR T cell‑mediated cytotoxicity, Sci Rep [3]. Amita Patnaik, et al. Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin Cancer Res.2015Oct1;21(19):4286-93. |